Therapeutic Workshop Details
Cardiovascular: Future Treatment Options in Cardiovascular Medicine
Thursday, October 11, 2007
3:30 PM
Sea Cliff
According to the World Health Organization, cardiovascular disease is the number one cause of death globally and is projected to remain the leading cause of death. Latest statistics indicate that more than 17.5 million people die each year from cardiovascular diseases, representing 30 percent of all global deaths. This panel will discuss emerging products and clinical developments and the positive impact this may have on current therapeutic standard-of-care, as well as discuss innovative pharmacologic approaches to the treatment and control of cardiovascular disease.
Moderators
- Michael G. King, Jr.; Director of Research, Acumen BioFin, a division of Rodman & Renshaw, LLC
Panelists
- Albert D. Friesen, PhD; President and Chief Executive Officer, Medicure Inc.
- Kevin V. Grimes; Senior Director, Clinical Research, KAI Pharmaceuticals, Inc.
- Charles J. Homcy, MD; President and Chief Executive Officer, Portola Pharmaceuticals, Inc.
- Andrew A. Wolff, MD, FACC; Chief Medical Officer, Senior Vice President, Clinical Research and Development, Cytokinetics, Inc.
- Lawrence K. Cohen, PhD; President and Chief Executive Officer, VIA Pharmaceuticals, Inc.
Who's Who
Michael King joined Rodman & Renshaw in May of 2005 as a Senior Biotechnology Analyst, covering a range of companies across a wide spectrum of market capitalizations and therapeutic categories. He is currently the Director of Research at Rodman & Renshaw. Prior to joining Rodman & Renshaw, King was a managing director and senior equity research analyst in the Health Care Group at Banc of America Securities LLC where he covered the biotechnology sector for three years. King joined Banc of America Securities in 2002 from Robertson Stephens, where he had been a managing director and senior biotechnology analyst since 1998. Prior to that, he served as senior biotechnology analyst at Vector Securities from 1996 to 1998 and at Dillon, Read & Co. from 1994 to 1996. King has also held positions at D. Blech & Company, Alex Brown and Sons, Hambrecht & Quist and Kidder, Peabody & Company. He earned a BBA with honors in finance from Baruch College. King was ranked fourth for his stock-picking accuracy in The Wall Street Journal's annual "Best on the Street" survey in 2001 and was given the Institutional Investor Home-Run Hitter award in 2000 for his coverage of OSI Pharmaceuticals. He was most recently ranked as the number 11 in the Institutional Investor poll of biotechnology analysts, and as a runner-up in the hedge fund subset of the poll.